Selecting peptides to optimize Th1 responses to an equine lentivirus using HLA-DR binding motifs and defined HIV-1 Th peptides

Immunogenetics

Volumn 55, Issue 7, 2003, Pages 508-514

  Fraser, Darrilyn G ^a   Mealey, Robert H ^a   McGuire, Travis C ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

EIAV; HIV 1; Th1

Indexed keywords

EPITOPE; GAG PROTEIN; HLA DR ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; POL PROTEIN; VIRUS PROTEIN; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; EQUINE INFECTIOUS ANEMIA VIRUS; HORSE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; LYMPHOCYTE PROLIFERATION; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN MOTIF; TH1 CELL; VIRUS INFECTION;

ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; DNA-BINDING PROTEINS; HIV-1; HLA-DR ANTIGENS; HORSES; HUMANS; LENTIVIRUSES, EQUINE; PEPTIDES; TRANSCRIPTION FACTORS;

ANIMALIA; EQUIDAE; EQUINE INFECTIOUS ANEMIA VIRUS; EQUUS CABALLUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRUS; RNA VIRUSES;

EID: 0242468301     PISSN: 00937711     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00251-003-0600-y     Document Type: Article

References (31)

1. Albright-Fraser DG, Reid R, Gerber V, Bailey E (1996) Polymorphism of DRA among equids. Immunogenetics 43:315-317, erratum Immunogenetics 44:487
2. Allen G, Yeargan M, Costa LRR, Cross R (1995) Major histocompatibility complex class I-restricted cytotoxic T lymphocyte responses in horses infected with equine herpesvirus 1. J Virol 69:606-612
3. + T cells that are dependent on MHC class II-bound peptide-flanking residues. J Immunol 169:739-749
4. Bernoco D, Antczak DF, Bailey E, Bell K, Bull RW, Byrns G, Guerin G, Lazary S, McClure J, Templeton J, Varewyck H (1987) Joint report of the fourth international workshop on lymphocyte alloantigens of the horse, Lexington, Kentucky, 12-22 October 1985. Anim Genet 18:81-94
5. + T cells. J Exp Med 184:863-871
6. de Quiros JC, Shupert WL, McNeil AC, Gea-Banacloche JC, Flanigan M, Savage A, Martino L, Weiskopf EE, Imamichi H, Zhang YM, Adelsburger J, Stevens R, Murphy PM, Zimmerman PA, Hallahan CW, Davey RT Jr, Connors M (2000) Resistance to replication of human immunodeficiency virus challenge in SCID-Hu mice engrafted with peripheral blood mononuclear cells of nonprogressors is mediated by CD8(+) T cells and associated with a proliferative response to p24 antigen. J Virol 74:2023-2028
7. Dzuris JL, Sidney J, Horton H, Correa R, Carter D, Chesnut RW, Watkins DI, Sette A (2001) Molecular determinants of peptide binding to two common rhesus macaque major histocompatibility complex class II molecules. J Virol 75:10958-10968
8. Fields GB, Noble RL (1990) Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int J Pept Protein Res 35:161-214
9. Fraser DG, Bailey E (1998) Polymorphism and multiple loci for the horse DQA gene. Immunogenetics 47:487-490
10. Fraser DG, Oaks JL, Brown WC, McGuire TC (2002) Identification of broadly recognized, T helper 1 lymphocyte epitopes in an equine lentivirus. Immunology 105:295-305
11. Hammond SA, Cook SJ, Lichtenstein DL, Issel CJ, Montelaro RC (1997) Maturation of the cellular and humoral immune responses to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process. J Virol 71:3840-3852
12. Hammond SA, Cook SJ, Falo LD Jr, Issel CJ, Montelaro RC (1999) A particulate viral protein vaccine reduces viral load and delays progression to disease in immunized ponies challenged with equine infectious anemia virus. Virology 254:37-49
13. Harrold SM, Cook SJ, Cook RF, Rushlow KE, Issel CJ, Montelaro RC (2000) Tissue sites of persistent infection and active replication of equine infectious anemia virus during acute disease and asymptomatic infection in experimentally infected equids. J Virol 74:3112-3121
14. + T-cell help in immunity to HIV. Vaccine 20:1961-1963
15. + T cells. Eur J Immunol 32:374-382
16. Imami N, Pires A, Hardy G, Wilson J, Gazzard B, Gotch F (2002) A balanced type 1/type 2 response is associated with long-term nonprogressive human immunodeficiency virus type 1 infection. J Virol 76:9011-9023
17. Kono Y (1969) Viremia and immunological responses in horses infected with equine infectious anemia virus. Natl Inst Anim Health Q (Tokyo) 9:1-9
18. + cytotoxic T-cell responses during chronic viral infection. J Virol 68:8056-8063
19. McGuire TC, Crawford TB, Henson JB (1971) Immunofluorescent localization of equine infectious anemia virus in tissue. Am J Pathol 62:283-294
20. + cytotoxic T lymphocytes from horses with equine infectious anemia virus recognize Env and Gag/PR proteins. J Virol 68:1459-1467
21. Mealey RH, Zhang B, Leib SR, Littke MH, McGuire TC (2003) Epitope specificity is critical for high and moderate avidity cytotoxic T lymphocytes associated with control of viral load and clinical disease in horses with equine infectious anemia virus. Virology 313:537-552
22. Oaks JL, Ulibarri C, Crawford TB (1999) Endothelial cell infection in vivo by equine infectious anaemia virus. J Gen Virol 80:2393-2397
23. O'Rourke K, Perryman LE, McGuire TC (1988) Antiviral, anti-glycoprotein and neutralizing antibodies in foals with equine infectious anaemia virus. J Gen Virol 69:667-674
24. Pearson JE, Coggins L (1979) Protocol for the immunodiffusion (Coggins) test for equine infectious anemia. Proc Am Assoc Vet Lab Diagn 22:449-462
25. Raabe ML, Issel CJ, Cook SJ, Cook RF, Woodson B, Montelaro RC (1998) Immunization with a recombinant envelope protein (rgp90) of EIAV produces a spectrum of vaccine efficacy ranging from lack of clinical disease to severe enhancement. Virology 245:151-162
26. Ridgely SL, Zhang B, McGuire TC (2003) Response of ELA-A1 horses immunized with lipopeptide containing an equine infectious anemia virus EL A-A1-restricted CTL epitope to virus challenge. Vaccine 21:491-506
27. Southwood S, Sidney J, Kondo A, del Guercio M-F, Appella E, Hoffman S, Kubo RT, Chesnut RW, Grey HM, Sette A (1998) Several Common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 160:3363-3373
28. Stephens RM, Casey JW, Rice NR (1986) Equine infectious anemia virus gag and pol genes: relatedness to visna and AIDS virus. Science 231:589-594
29. Terasaki PI, Bernoco D, Park MS, Ozturk G, Iwaki Y (1978) Microdroplet testing for HLA-A, -B, -C and -D antigens. The Philip Levine Award Lecture. Am J Clin Pathol 69:103-120
30. Vitiello A, Ishioka G, Grey HM, Rose R, Farness P, LaFond R, Yuan L, Chisari FV, Furze J, Bartholomeuz R, Chesnut RW (1995) Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. J Clin Invest 95:341-349
31. Wilson CC, Palmer B, Southwood S, Sidney J, Higashimoto Y, Appella E, Chesnut R, Sette A, Livingston BD (2001) Identification and antigenicity of broadly cross-reactive and conserved human immunodeficiency virus type 1-derived helper T-lymphocyte epitopes. J Virol 75:4195-4207